CONKO-001: FINAL RESULTS OF THE RANDOMIZED, PROSPECTIVE, MULTICENTER PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE VERSUS OBSERVATION IN PATIENTS WITH RESECTED PANCREATIC CANCER (PC)

被引：0
|
作者：
Riess, H.
Neuhaus, P.
Post, S.
Gellert, K.
Ridwelski, K.
Schramm, H.
Zuelke, C.
Fahlke, J.
Langrehr, J.
Oettle, H.
机构：
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：45 / 46
页数：2
相关论文
共 50 条
  • [31] CXCR4, CXCR7 and CXCL12 expression is not a predictive factor in patients with resected pancreatic cancer - results from the CONKO-001 trial
    Striefler, J. K.
    Wislocka, L.
    Sinn, M.
    Denkert, C.
    Juehling, A.
    Pelzer, U.
    Bischoff, S.
    Bahra, M.
    Oettle, H.
    Blaeker, H.
    Riess, H.
    Lohneis, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 258 - 259
  • [32] A randomized phase III trial of postoperative adjuvant chemotherapy versus surgery alone for radically resected gastric cancer (GC):: Final results of 9602 GOIM study
    De Vita, F.
    Giuliani, F.
    Orditura, M.
    Maiello, E.
    Manzione, L.
    Galizia, G.
    Romito, S.
    Gebbia, V
    Carteni, G.
    Catalano, G.
    Colucci, G.
    ANNALS OF ONCOLOGY, 2006, 17 : XI54 - XI54
  • [33] Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial
    Sinn, M.
    Riess, H.
    Sinn, B. V.
    Stieler, J. M.
    Pelzer, U.
    Striefler, J. K.
    Oettle, H.
    Bahra, M.
    Denkert, C.
    Blaeker, H.
    Lohneis, P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (12) : 1546 - 1554
  • [34] Phase II trial of postoperative adjuvant gemcitabine and cisplatin chemotherapy followed by chemoradiation with gemcitabine in patients with resected pancreatic cancer.
    Kwon, J. H.
    Chie, E. K.
    Kim, J. H.
    Im, S.
    Oh, D.
    Kim, Y.
    Han, S.
    Lee, K.
    Jang, J.
    Kim, T.
    Kim, J. S.
    Han, H. S.
    Kim, S.
    Yoon, Y. B.
    Bang, Y.
    Ha, S. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma
    Takada, T
    Amano, H
    Yasuda, H
    Nimura, Y
    Matsushiro, T
    Kato, H
    Nagakawa, T
    Nakayama, T
    CANCER, 2002, 95 (08) : 1685 - 1695
  • [36] Original Research Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma-A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials
    Kurreck, Annika
    Weckwerth, Johanna
    Modest, Dominik P.
    Striefler, Jana K.
    Bahra, Marcus
    Bischoff, Sven
    Pelzer, Uwe
    Oettle, Helmut
    Kruger, Stephan
    Riess, Hanno
    Sinn, Marianne
    EUROPEAN JOURNAL OF CANCER, 2021, 150 : 250 - 259
  • [37] APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).
    Tempero, Margaret A.
    Cardin, Dana Backlund
    Goldstein, David
    O'Reilly, Eileen Mary
    Philip, Agop Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Li, Mingyu
    Lu, Brian D.
    Biankin, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [38] CXCR4, CXCR7 and CXCL12 expression is not a prognostic predictive factor in patients with resected pancreatic cancer - results from the CONKO-001 trial
    Striefler, J.
    Wislocka, L.
    Sinn, M.
    Pelzer, U.
    Denkert, C.
    Juehling, A.
    Bischoff, S.
    Bahra, M.
    Hendrik, B.
    Oettle, H.
    Riess, H.
    Lohneis, P.
    ANNALS OF ONCOLOGY, 2016, 27 : 104 - 104
  • [39] Results of the conko 003 trial.: A randomized second line trial in patients with gemcitabine refractory advanced pancreatic cancer
    Pelzer, U.
    Stieler, J.
    Schwaner, I.
    Heil, G.
    Seraphin, J.
    Goerner, M.
    Moelle, M.
    Greten, T.
    Lakner, V.
    Kubica, K.
    Hilbig, A.
    Roll, L.
    Goerke, A.
    Sinn, M.
    Doerken, B.
    Riess, H.
    Oettle, H.
    ONKOLOGIE, 2008, 31 : 98 - 98
  • [40] ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.
    Neoptolemos, John P.
    Palmer, Dan
    Ghaneh, Paula
    Valle, Juan W.
    Cunningham, David
    Wadsley, Jonathan
    Meyer, Tim
    Anthoney, Alan
    Glimelius, Bengt
    Falk, Stephen
    Segersvard, Ralf
    Izbicki, Jakob R.
    Middleton, Gary William
    Ross, Paul J.
    Wasan, Harpreet
    Mcdonald, Alec
    Crosby, Tom David Lewis
    Psarelli, Eftychia Eirini
    Hammel, Pascal
    Buchler, Markus W.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)
12345